Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Publication year range
1.
Zhongguo Dang Dai Er Ke Za Zhi ; 26(7): 743-749, 2024 Jul 15.
Article in Chinese | MEDLINE | ID: mdl-39014952

ABSTRACT

OBJECTIVES: To investigate the efficacy and safety of nusinersen sodium in the treatment of children with spinal muscular atrophy (SMA). METHODS: A retrospective analysis was conducted on the clinical data of 50 children with 5q SMA who received nusinersen sodium treatment and multidisciplinary treatment management in Shanxi Children's Hospital from February 2022 to February 2024. RESULTS: Compared with the baseline data, 67% (8/12), 74% (35/47), and 74% (35/47) of the SMA children had a clinically significant improvement in the scores of Philadelphia Infant Test of Neuromuscular Disorders, Hammersmith Functional Motor Scale Expanded, and Revised Upper Limb Module, respectively, and the distance of 6-minute walking test increased from 207.00 (179.00, 281.50) meters to 233.00 (205.25, 287.50) meters (P<0.05) after nusinersen sodium treatment. Of all 50 children with SMA, 24 (48%) showed good tolerability after administration, with no significant or persistent abnormalities observed in 2 034 laboratory test results, and furthermore, there were no serious or immunological adverse events related to the treatment. After treatment, there was a significant change in forced vital capacity as a percentage of the predicted value in 27 children with restrictive ventilatory dysfunction, as well as a significant change in the level of 25-(OH) vitamin D in 15 children with vitamin D deficiency (P<0.05). CONCLUSIONS: For children with SMA, treatment with nusinersen sodium can continuously improve the response rates of motor function scales, with good tolerability and safety.


Subject(s)
Oligonucleotides , Humans , Male , Female , Retrospective Studies , Oligonucleotides/therapeutic use , Oligonucleotides/adverse effects , Infant , Child, Preschool , Muscular Atrophy, Spinal/drug therapy , Child , Treatment Outcome , Spinal Muscular Atrophies of Childhood/drug therapy
2.
Clin Neurol Neurosurg ; 194: 105918, 2020 07.
Article in English | MEDLINE | ID: mdl-32446122

ABSTRACT

OBJECTIVES: Percutaneous transforaminal endoscopic decompression (PTED) under local anesthesia is rarely performed for lumbar spinal stenosis (LSS) with degenerative lumbar spondylolisthesis (DLS) because of the limited field of vision, inherent instability, etc. The objective of this study was to describe the procedure of the PTED technique and to demonstrate the early clinical outcomes. PATIENTS AND METHODS: From January 2017 to January 2019, 40 consecutive patients aged 60 and older were diagnosed with LSS with DLS in our institution and underwent PTED. All patient were followed up to 1 year postoperatively. The clinical outcomes were evaluated using the visual analogue scale (VAS), Oswestry Disability Index (ODI) and modified MacNab criteria. RESULTS: The mean age was 70.2 ± 7.1 years. Follow-up ranged from 12 to 24 months. The mean ± SD values of the preoperative VAS leg pain and ODI scores were 7.5 ± 1.1 and 67.3 ± 9.3, respectively. The scores improved to 2.2 ± 1.1 and 20.7 ± 8.1 at 12 months postoperatively. The outcomes of the modified MacNab criteria showed that 87.5 % of patients obtained a good-to-excellent rate. The percent slippage of spondylolisthesis before surgery (10.8 ± 2.6 %) and at the end of follow-up (11.0 ± 2.4 %) was not significantly different. One patient had a dural tear and intracranial hypertension, and one patient had tibialis anterior weakness. CONCLUSION: PTED under local anesthesia could be an effective treatment method for LSS with DLS in elderly patients. However, potential complications still require further evaluation.


Subject(s)
Decompression, Surgical/methods , Endoscopy/methods , Lumbosacral Region/surgery , Spinal Stenosis/surgery , Spondylolisthesis/surgery , Aged , Aged, 80 and over , Disability Evaluation , Female , Follow-Up Studies , Humans , Intervertebral Disc Degeneration/surgery , Lumbosacral Region/diagnostic imaging , Magnetic Resonance Imaging , Male , Middle Aged , Pain Measurement , Postoperative Complications/epidemiology , Retrospective Studies , Spinal Stenosis/diagnostic imaging , Spondylolisthesis/diagnostic imaging , Tomography, X-Ray Computed , Treatment Outcome
3.
Mol Med Rep ; 16(2): 1810-1816, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28627643

ABSTRACT

Renal ischemia/reperfusion (I/R) injury is a debilitating condition that leads to loss renal function and damage to kidney tissue in the majority of patients with acute kidney disease. Previous studies have indicated that autophagy serves a protective function in renal I/R injury. In the present study, the effect of the anthelmintic niclosamide in the regulation of inflammatory responses in kidney I/R was investigated. A total of 40 Sprague-Dawley rats were randomly divided into the following 5 groups (n=8 in each group): Sham group; renal I/R injury; renal I/R injury plus 3­methyladenine (3­MA) treatment (15 mg/kg); renal I/R injury plus niclosamide (25 mg/kg); and renal I/R injury plus rapamycin (10 mg/kg). The expression levels of autophagy­associated proteins in kidney samples obtained from rats with I/R injury were examined using reverse transcription­quantitative polymerase chain reaction and western blotting techniques. In addition, histopathological alterations, the expression of cytokines and renal function were evaluated. Treatment with niclosamide was associated with induction of autophagy and an overall improvement in renal function. There was an increased expression of autophagosome­associated proteins, suggesting a strong correlation between autophagy and improvement of renal function. The increased levels of anti­inflammatory cytokines and decreased levels of pro­inflammatory cytokines provided additional evidence that niclosamide may be effective for the treatment of renal I/R injury. Clinical studies are required to further validate the results of the present study.


Subject(s)
Autophagy , Cytokines/metabolism , Inflammation Mediators/metabolism , Kidney/pathology , Niclosamide/therapeutic use , Reperfusion Injury/drug therapy , Reperfusion Injury/pathology , Animals , Autophagosomes/drug effects , Autophagosomes/metabolism , Autophagosomes/ultrastructure , Autophagy/drug effects , Beclin-1/metabolism , Biomarkers/metabolism , Blood Urea Nitrogen , Creatinine/blood , HMGB1 Protein/metabolism , Kidney/drug effects , Kidney/physiopathology , Kidney/ultrastructure , Kidney Function Tests , Male , Niclosamide/pharmacology , Rats, Sprague-Dawley , Reperfusion Injury/blood , Reperfusion Injury/physiopathology , Treatment Outcome
4.
Mol Neurobiol ; 54(6): 4292-4302, 2017 08.
Article in English | MEDLINE | ID: mdl-27339879

ABSTRACT

Caspase family has been recognized to be involved in dopaminergic (DA) neuronal death and to exert an unfavorable role in Parkinson's disease (PD) pathology. Our previous study has revealed that caspase-1, as an important component of NLRP3 inflammasome, induces microglia-mediated neuroinflammation in the pathogenesis of PD. However, the role of caspase-1 in DA neuronal degeneration in the onset of PD remains unclear. Here, we showed that caspase-1 knockout ameliorated DA neuronal loss and dyskinesia in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine/probenecid (MPTP/p)-induced PD model mice. We further found that caspase-1 knockout decreased MPTP/p-induced caspase-7 cleavage, subsequently inhibited nuclear translocation of poly (ADP-ribose) polymerase 1 (PARP1), and reduced the release of apoptosis-inducing factor (AIF). Consistently, we demonstrated that caspase-1 inhibitor suppressed caspase-7/PARP1/AIF-mediated apoptosis pathway by 1-methyl-4-phenylpyridinium ion (MPP+) stimulation in SH-SY5Y cells. Caspase-7 overexpression reduced the protective effects of caspase-1 inhibitor on SH-SY5Y cell apoptosis. Collectively, our results have revealed that caspase-1 regulates DA neuronal death in the pathogenesis of PD in mice via caspase-7/PARP1/AIF pathway. These findings will shed new insight into the potential of caspase-1 as a target for PD therapy.


Subject(s)
Apoptosis Inducing Factor/metabolism , Caspase 1/deficiency , Caspase 7/metabolism , Dopaminergic Neurons/pathology , Parkinson Disease/enzymology , Parkinson Disease/pathology , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Amino Acid Chloromethyl Ketones/pharmacology , Animals , Caspase 1/metabolism , Cell Death/drug effects , Cell Line, Tumor , Disease Models, Animal , Dopaminergic Neurons/metabolism , Down-Regulation/drug effects , Enzyme Activation/drug effects , Humans , Mice, Knockout , Models, Biological , Motor Activity/drug effects , Poly(ADP-ribose) Polymerases/metabolism
5.
Zhongguo Zhong Yao Za Zhi ; 40(11): 2068-76, 2015 Jun.
Article in Chinese | MEDLINE | ID: mdl-26552159

ABSTRACT

MISA (MicroSAtelite) software was employed to screen SSRs in 68 787 contigs of Swertia mussotii transcriptome sequences. 5 610 SSRs were distributed in 5 099 contigs which accounted for 7.41% of 68 787 contigs. There are 220 kinds of SSR motifs existing in S. mussotii transcriptome. On average, SSRs occurred every 12.60 kb in length. In the SSRs, the tri-nucleotide repeat motif was the most abundant (45.99%), followed by the di-nucleotide (41.62%). AT/TA and AAT/TTA were the main types of motif in di-, tri-nucleotide repeats. The repeat numbers of SSRs which from S. mussotii transcriptome SSRs were mainly from 5 to 10 and motif length of them mostly ranged from 12 bp to 30 bp. A total of 30 651 contigs were annotated, and only 1 447 SSRs were occurred in protein-coding regions. In the six repeat motifs, tri-nucleotide repeats were the most abundant in coding regions (928). There are abundant SSRs in S. mussotii transcriptome with high frequency and various types, indicating their usefulness in theory. This research may lay the foundation for designing the targeted SSR primers and developing SSR molecular markers by mining the information of SSRs loci in S. mussotii transcriptome sequences data.


Subject(s)
Data Mining , Medicine, Tibetan Traditional , Microsatellite Repeats , Swertia/genetics , Transcriptome , Plants, Medicinal/genetics
6.
Zhongguo Zhong Yao Za Zhi ; 30(19): 1496-500, 2005 Oct.
Article in Chinese | MEDLINE | ID: mdl-16335816

ABSTRACT

The traditional medicinal herbs are natural product, and have no obviously toxic action and side effect, and their resources are extensive. The adverse effects produced by aldose reductase inhibitors in traditional medicinal herbs are less than those from chemical synthesis and micro-organism, they can effectively prevent and delay diabetic complication, such as diabetic nephropathy, vasculopathy, retinopathy, peripheral neuropathy, and so on. They will have a wonderful respect. Flavonoid compounds and their derivates from traditional medicinal herbs are active inhibitors to aldose reductase, such as quercetin, silymarin, puerarin, baicalim, berberine and so on. In addition, some compound preparations show more strongly activity in inhibiting aldose reductase and degrading sorbitol contents, such as Shendan in traditional medicinal herbs being active inhibitors and Jianyi capsule, Jinmaitong composita, Liuwei Di-huang pill, et al. The progresses definite functions of treating diabetes complications have been reviewed.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Drugs, Chinese Herbal/pharmacology , Enzyme Inhibitors , Plants, Medicinal , Quercetin/pharmacology , Aldehyde Reductase/metabolism , Animals , Diabetic Nephropathies/metabolism , Drug Combinations , Enzyme Inhibitors/metabolism , Humans , Isoflavones/isolation & purification , Isoflavones/pharmacology , Plants, Medicinal/chemistry , Quercetin/isolation & purification , Silybin , Silymarin/isolation & purification , Silymarin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL